A5024260008- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Peripheral Neuropathies and Disorders
- Peptidase Inhibition and Analysis
- Parathyroid Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Bone and Joint Diseases
- Histone Deacetylase Inhibitors Research
- Immunodeficiency and Autoimmune Disorders
- T-cell and Retrovirus Studies
- Hematological disorders and diagnostics
- Cancer therapeutics and mechanisms
- Viral-associated cancers and disorders
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Myeloid Leukemia Treatments
- Autoimmune Bullous Skin Diseases
- 14-3-3 protein interactions
- Neutropenia and Cancer Infections
University of Padua
2015-2024
Sarah Cannon
2023
University of Arkansas for Medical Sciences
2018
University of Utah
2011-2013
Istituto Oncologico Veneto
2005
Veneto Institute of Molecular Medicine
2005
Ospedale San Bortolo
2005
// Antonella Teramo 1, 2, * , Gregorio Barilà Giulia Calabretto 2 Chiara Ercolin Thierry Lamy 3 Aline Moignet Mikael Roussel 4 Cédric Pastoret Matteo Leoncin 1 Cristina Gattazzo Anna Cabrelle Elisa Boscaro Sara Teolato Pagnin Tamara Berno Elena De March Monica Facco Francesco Piazza Livio Trentin Gianpietro Semenzato and Renato Zambello Padua University School of Medicine, Department Hematology Clinical Immunology Branch, Padua, Italy Venetian Institute Molecular Medicine (VIMM), Hematology,...
<h2>Abstract</h2><h3>Aim</h3> Defining the epidemiology of systemic and cardiac amyloidosis (CA) is a contemporary challenge. The present study aimed to estimate incidence time trends in amyloidosis-related hospitalizations (AH) Veneto Region (5 million inhabitants, Northeastern Italy). <h3>Methods</h3> International Classification Diseases (ICD-9) codes were used identify AH from 2010 2020. defined as any hospitalization with discharge summary reporting an ICD-9 code for amyloidosis....
Daratumumab demonstrated activity in the treatment of AL amyloidosis two recently concluded phase II clinical trials relapsed and refractory patients. Its role upfront therapy is under evaluation a III study. In this report we evaluated safety efficacy 28-day cycles daratumumab (single agent or combined with bortezomib lenalidomide) 72 previously treated patients multiple myeloma amyloidosis. Fifty (69%) were to last line therapy. After eight infusions daratumumab, 59 (82%) achieved...
The ubiquitin-proteasome pathway regulates bone formation through osteoblast differentiation. We analyzed variation alkaline phosphatase (ALP) during carfilzomib treatment. Data from 38 patients enrolled in the PX-171-003 and 29 PX-171-004 studies, for with relapsed/refractory myeloma, were analyzed. All received 20 mg/m(2) of on Days 1, 2, 8, 9, 15, 16 a 28-day cycle. Sixty-seven ALP data evaluable. In PX-171-003, ORR (>PR) was 18% clinical benefit response (CBR; >MR) 26%, while PX-171-004,...
To evaluate long-term lenalidomide neurotoxicity and correlation with cumulative dose hematologic response.Nineteen myeloma patients (7 men, mean age 63.2 years) underwent clinical neurophysiologic assessment at baseline 2 (8 patients, group A) or 5 years (11 B) after starting therapy for relapsed/refractory multiple myeloma. Neuropathy was scored Total Score version (TNSc). Lenalidomide correlated severity of neuropathy response.At enrollment, 7/19 (3 in A, 4 had signs secondary to previous...
// Andrea Visentin 1, 2 , Silvia Imbergamo 1 Federica Frezzato Marco Pizzi 3 Roberta Bertorelle 4 Edoardo Scomazzon Tamara Berno Marcello Riva Elisa Piva 5 Monica Facco Francesco Piazza Gianpietro Semenzato and Livio Trentin Hematology Clinical Immunology Unit, Department of Medicine, University Padua, Italy Venetian Institute Molecular Centro di Eccellenza per la Ricerca Biomedica Avanzata, General Pathology Cytopathology Diagnostic Oncology Veneto IOV-IRCSS, Unity Laboratory Correspondence...
The etiology of chronic large granular lymphocyte proliferations is largely unknown. Although these disorders are characterized by the expansion different cell types (T and natural killer) with specific genetic features abnormalities, several lines evidence suggest a common pathogenetic mechanism. According to this interpretation, we speculated that in patients killer-type lymphoproliferative disorder, together killer cells, also T lymphocytes undergo persistent antigenic pressure, possibly...
The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate symptomatic SARS-CoV-2 infection in patients at increased risk inadequate response vaccination. However, was tested a few studies that included with hematological malignancies, even if this population an unfavorable outcomes following (with high rates hospitalization, intensive care unit admission, and mortality) poor significant immunization vaccines. We performed real-life prospective cohort study...
Renal injury related to Waldenström macroglobulinemia (WM) occurs in approximately 3% of patients. Kidney biopsy is crucial discriminate between distinct histopathological entities such as glomerular (amyloidotic and non-amyloidotic), tubulo-interstitial non-paraprotein mediated renal damage. In this context, disease characterization, management, relationship renal, hematological response have been poorly explored. We collected clinical, genetic laboratory data seven cases biopsy-proven...
Thromboses represent a major cause of morbidity and mortality in polycythemia vera but the contributing mechanisms are not fully described. To evaluate whether environmental conditions such as altitude/hypoxia could impact thrombosis history, we retrospectively analyzed history 71 patients living at an elevation 5000 feet or more Salt Lake City (SLC) area 166 near sea level Baltimore (BLM) area. The SLC cohort was older with longer disease duration. No significant differences type...
Abstract Lenalidomide, an immunomodulatory drug used in myeloma therapy, has been claimed to be less neurotoxic than thalidomide, but evidence is still weak. We prospectively assessed lenalidomide safety patients evaluate whether it would induce or modify a previously ensued chemotherapy‐induced peripheral neuropathy ( CIPN ). Thirty consecutive (17 men, mean age 63.7 ± 9.4) treated with bortezomib and/or thalidomide and starting on (25 mg/day for 21‐day cycles) relapsed refractory were at...
Waldenström macroglobulinemia (WM) is a rare indolent non-Hodgkin lymphoma characterized by the expansion in bone marrow of monoclonal IgM (mIgM)-secreting lymphoplasmacytic cells.1–3 Many patients live with WM during elderly age experiencing comorbidities that must be considered management disease. Age ≥65 years at start therapy portends worse outcome, according to international prognostic scoring system on (IPSSWM) and revised-IPSSWM (r-IPSSWM).4 However, survival baseline characteristics...
We evaluated differences in density and 18F-FDG PET/MRI features of lytic bone lesions (LBLs) identified by whole-body low-dose CT (WB-LDCT) patients affected newly diagnosed multiple myeloma (MM). In 18 MM patients, 135 unequivocal LBLs WB-LDCT were characterized for inner (negative or positive Hounsfield unit (HU)), where negative (HU < 0) characterizes normal yellow marrow whereas HU correlates with tissue-like infiltrative pattern. The same analyzed PET/DWI-MRI, registering DWI signal...
Neuropathy is a frequent complication of Waldenström's macroglobulinemia (WM), the most common being demyelinating polyneuropathy with anti-myelin associated glycoprotein (MAG) antibodies, but also cryoglobulins, vasculitis, neurolymphomatosis, and amyloidosis. We describe patient IgM/kappa WM who presented severe, not length-dependent, peripheral neuropathy as clinical onset IgM/kappa-related amyloidosis.A 69-year-old woman came to our attention for weight loss, gait imbalance sensory loss...
Identifying the best gene expression pattern associated with low-risk disease in patients newly diagnosed multiple myeloma (MM) is important to direct clinical treatments. The MM Survival Index14 (MMSI14) was developed from GEP data sets of 22 normal plasma cells (NPC), 5 cell lines (MMCL), 44 monoclonal gammopathy undetermined significance (MGUS), and 351 patients. R/bioconductor siggenes package were used obtain heatmap, boxplot histogram whose results then analyzed by Kaplan-Meier...